Jinzi Jason Wu - Jul 18, 2023 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Director
Signature
/s/ Dennis Hom, Attorney-in-Fact
Stock symbol
SGMT
Transactions as of
Jul 18, 2023
Transactions value $
$0
Form type
4
Date filed
7/20/2023, 04:19 PM
Previous filing
Jul 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMT Series A Common Stock Conversion of derivative security +1.65M 1.65M Jul 18, 2023 By AP11 Limited F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Series E Preferred Stock Conversion of derivative security $0 -108M -100% $0.00* 0 Jul 18, 2023 Series A Common Stock 1.36M By AP11 Limited F1, F2
transaction SGMT Series F Preferred Stock Conversion of derivative security $0 -23M -100% $0.00* 0 Jul 18, 2023 Series A Common Stock 290K By AP11 Limited F1, F2
transaction SGMT Stock Option (Right to Buy) Disposed to Issuer $0 -23.2K -100% $0.00* 0 Jul 18, 2023 Common Stock 23.2K $6.36 Direct F3, F4
transaction SGMT Stock Option (Right to Buy) Award $0 +23.2K $0.00 23.2K Jul 18, 2023 Series A Common Stock 23.2K $6.36 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date.
F2 Shares held directly by AP11 Limited, a subsidiary of Ascletis Pharma Inc. ("Ascletis"). The Reporting Person is founder, chairman and chief executive officer of Ascletis. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F3 Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F4 The shares underlying this option are fully vested and exercisable as of the date hereof.